|
|
|
- 您 可 以 信 任 的 醫 學 圖 書 智 庫 |
|
www.leaderbook.com.tw 02-27332592
(熱病) The Sanford Guide to Antimicrobial Therapy 42/e 2012(現貨供應)
-感染科
- 編號： 0-0-0001930808704
- 作者：Gilbert
- 原價-850 - (熱賣價)750 - 節省 ↓12%
- 加入購物車
推薦指數：
- 內容介紹
熱病 The Sanford Guide to Antimicrobial Therapy 42/e 2012
4.5 x 6.5 inches (Pocket Edition)
ISBN: 978-1-930808-70-6
The 2012 pocket edition is 20% thinner and lighter in weight than the 2011 edition due to new production methods, making the 2012 pocket edition handier than ever. We have also increased contrast of the text for greatly improved readability!
The 42nd edition of The Sanford Guide to Antimicrobial Therapy is available in a wide array of formats: the pocket edition, somewhat larger spiral bound edition, and larger library edition in print; Apps for iOS and Android devices; and the Web Edition. The digital editions provide us with a platform to update content regularly as developments warrant. The print editions continue to be our annual
-snapshot- of the current state of the field of antimicrobial therapy.
Highlights of the 42nd edition include the following areas:
- Resistance to antibacterial agents is increasing at an alarming pace. Materials on management of resistant gram-positive organisms, such as MRSA, and multi-drug resistant gram-negative bacilli, such as E. coli, (Tables 2, 5 and 6 in print) have been extensively updated and expanded. Despite years of availability, the polymyxin drugs are becoming more important options for treatment of gram-negative infections. Expanded discussion and dosing regimens for Polymyxin B and Polymyxin E (Colistin) are included.
- There is increasing clinical application of continuous, or prolonged, infusion of antibacterials for those drugs where optimal efficacy correlates with time above MIC of the target bacteria: cefepime, ceftazidime, doripenem, meropenem, piperacillin-tazobactam. A new table (10D in print) in all editions suggests regimens for continuous or prolonged infusion of these agents.
- Hepatitis C (HCV) infects over 175 million people worldwide. Two new HCV protease inhibitors, boceprevir and telaprevir, were approved in 2011 for treatment of HCV. Many more drugs are in development in early 2012. Developments in this field are covered in the 42nd edition, in the Web Edition, in The Sanford Guide to HIV/AIDS Therapy 2012 (20th edition) and in the Sanford Guide to Hepatitis Diagnosis and Treatment App (iOS and Android).
- Antiretroviral therapy options continue to expand with the approval of new drugs, such as rilpivirine, and new combination formulations of ARV drugs such as Complera.
- A newly approved macrolide, fidaxomicin, is included for treatment of moderate to severe C. difficille toxin-mediated diarrhea.
|
|
|
|
|
└ 返回上一頁
|
|
